KRAS and non-small cell lung carcinoma: That changed on May 28, 2021, when the United States Food and Drug Administration (FDA) granted accelerated approval to sotorasib for second-line or later treatment of patients with locally advanced or metastatic KRAS G12C mutant NSCLC.